Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1771718
PUBLISHER: Grand View Research | PRODUCT CODE: 1771718
Germany Pharmaceutical Market Size, Share & Trends Analysis Report By Molecule Type, By Product, By Type, By Disease, By Age Group, By Route Of Administration, By Distribution Channel, By Country, And Segment Forecasts, 2025 - 2033
PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Germany Pharmaceuticals Market Growth & Trends:
The Germany pharmaceuticals market size is estimated to reach USD 151.51 billion by 2033, registering to grow at a CAGR of 5.31% from 2025 to 2033 according to a new report by Grand View Research, Inc. Factors such as the rising prevalence of acute and chronic diseases and increasing R&D expenditure by pharmaceutical companies are expected to drive the market.
Furthermore, rising clinical trials and approval of novel immune-suppressive therapies are anticipated to propel market growth. For instance, in June 2020, Sandoz International GmbH launched Dailiport capsules (generic tacrolimus) in Germany and other European countries. Dailiport capsules are indicated for adult kidney and liver transplant patients.
In addition, the export of pharmaceutical products by pharmaceutical companies in Germany to various countries is expected to fuel market growth. For instance, according to Germany Trade and Invest, in China, 22.0% of imported pharmaceutical products are from German companies.
Key players entering into strategic initiatives such as partnership, licensing, acquisition, and collaboration to expand and strengthen their regional presence is expected to boost the market growth. For instance, in November 2019, Bristol-Myers Squibb Company acquired Celgene Corporation. This acquisition was aimed at helping the company expand its oncology portfolio worldwide and develop innovative medicines.
In addition, rising funds by organizations for the development of pipeline drugs are anticipated to accelerate market growth. For instance, in January 2019, Atriva Therapeutics GmbH closed its series A financing led by Meneldor and High-Tech Grunderfonds GmbH (HTGF) for its lead drug candidate ATR-002. This drug candidate is developed against influenza infection and other respiratory infections.
Various other organizations, such as the European Cancer Organisation (ECCO), European Cancer Patient Coalition (ECPC), and European Organisation for Research and Treatment of Cancer (EORTC) provide funds for cancer research programs and treatment plans.
Furthermore, increasing the availability of generic drugs at a lower price is expected to boost the market growth. For instance, in July 2019, Sandoz of Novartis AG launched a generic version of gefitinib for locally advanced or metastatic NSCLC. The launch of the generic version is estimated to increase the number of patients treated due to the favorable cost of the drug.
Germany Pharmaceuticals Market Report Highlights:
- Conventional drugs (small molecules) dominated the market with a revenue share of 54.74% in 2024.
- The branded segment dominated the Germany pharmaceutical industry with a revenue share of 66.86% in 2024
- The prescription segment dominated the market with a revenue share of 86.76% in 2024.
- The cancer segment dominated the market with a revenue share of 18.06% in 2024.
- The oral segment dominated the market with a revenue share of 57.53% in 2024.
- The adult segment dominated the market with a revenue share of 62.84% in 2024
- The hospital pharmacy segment dominated the market with a revenue share of 53.53% in 2024
Product Code: GVR-4-68039-118-0
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Germany Pharmaceutical Market Variables, Trends, & Scope
- 3.1. Parent Market Outlook
- 3.2. Ancillary Market Outlook
- 3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.1.1. Advancement in therapeutics and robust product pipeline
- 3.3.1.2. Rise in pharmaceutical r&d spending
- 3.3.1.3. Rise in pharmaceutical r&d spending
- 3.3.2. Market Restraints Analysis
- 3.3.2.1. Patent expiration of key market drugs
- 3.3.2.2. Pricing pressures on bio/pharmaceutical companies
- 3.3.2.3. Stringent regulatory scenario
- 3.3.1. Market Drivers Analysis
- 3.4. Dopamine Agonist Analysis Tools
- 3.4.1. Porter's Analysis
- 3.4.1.1. Bargaining power of the suppliers
- 3.4.1.2. Bargaining power of the buyers
- 3.4.1.3. Threats of substitution
- 3.4.1.4. Threats from new entrants
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Economic and Social landscape
- 3.4.2.3. Technological landscape
- 3.4.2.4. Environmental landscape
- 3.4.2.5. Legal landscape
- 3.4.1. Porter's Analysis
- 3.5. Pipeline Analysis
- 3.5.1. Phase 1
- 3.5.2. Phase 2
- 3.5.3. Phase 3
Chapter 4. Germany Pharmaceutical Market: By Drug Estimates & Trend Analysis
- 4.1. Germany Pharmaceutical Market: Drug Segment Dashboard
- 4.2. Germany Pharmaceutical Market: By Drug Movement Analysis, 2024 & 2033 (USD Million)
- 4.3. Biologics & Biosimilars (Large Molecules)
- 4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.2. Monoclonal Antibodies
- 4.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.3. Vaccines
- 4.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.4. Cell & Gene Therapy
- 4.3.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.5. Others
- 4.3.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4. Conventional Drugs (Small Molecules)
- 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Germany Pharmaceutical Market: Type Estimates & Trend Analysis
- 5.1. Germany Pharmaceutical Market: Type Segment Dashboard
- 5.2. Germany Pharmaceutical Market: By Product Movement Analysis, 2024 & 2033 (USD Million)
- 5.3. Prescription
- 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4. OTC
- 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Germany Pharmaceutical Market: Product Estimates & Trend Analysis
- 6.1. Germany Pharmaceutical Market: Product Segment Dashboard
- 6.2. Germany Pharmaceutical Market: By Product Movement Analysis, 2024 & 2033 (USD Million)
- 6.3. Branded
- 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4. Generics
- 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Germany Pharmaceutical Market: Disease Estimates & Trend Analysis
- 7.1. Germany Pharmaceutical Market: Disease Segment Dashboard
- 7.2. Germany Pharmaceutical Market: By Disease Movement Analysis, 2024 & 2033 (USD Million)
- 7.3. Cardiovascular diseases
- 7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4. Cancer
- 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Diabetes
- 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Infectious diseases
- 7.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. Neurological disorders
- 7.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8. Respiratory diseases
- 7.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.9. Autoimmune diseases
- 7.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.10. Mental health disorders
- 7.10.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.11. Gastrointestinal disorders
- 7.11.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.12. Women's Health Diseases
- 7.12.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.13. Genetic and Rare genetic diseases
- 7.13.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.14. Dermatological conditions
- 7.14.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.15. Obesity
- 7.15.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.16. Renal diseases
- 7.16.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.17. Liver conditions
- 7.17.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.18. Hematological disorders
- 7.18.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.19. Eye conditions
- 7.19.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.20. Infertility conditions
- 7.20.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.21. Endocrine disorders
- 7.21.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.22. Allergies
- 7.22.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.23. Others
- 7.23.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Germany Pharmaceutical Market: Route of Administration Estimates & Trend Analysis
- 8.1. Germany Pharmaceutical Market: Route of Administration Segment Dashboard
- 8.2. Germany Pharmaceutical Market: By Route of Administration Movement Analysis, 2024 & 2033 (USD Million)
- 8.3. Oral
- 8.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.3.2. Tablets
- 8.3.3. Capsules
- 8.3.4. Suspensions
- 8.3.5. Other
- 8.4. Topical
- 8.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5. Parenteral
- 8.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.2. Intravenous
- 8.5.3. Intramuscular
- 8.6. Inhalations
- 8.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7. Other Routes of Administration
- 8.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Germany Pharmaceutical Market: Age Group Estimates & Trend Analysis
- 9.1. Germany Pharmaceutical Market: Age Group Segment Dashboard
- 9.2. Germany Pharmaceutical Market: By Age Group Movement Analysis, 2024 & 2033 (USD Million)
- 9.3. Children & Adolescents
- 9.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4. Adults
- 9.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5. Geriatric
- 9.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 10. Germany Pharmaceutical Market: Distribution Channel Estimates & Trend Analysis
- 10.1. Germany Pharmaceutical Market: Distribution Channel Segment Dashboard
- 10.2. Germany Pharmaceutical Market: By Distribution Channel Movement Analysis, 2024 & 2033 (USD Million)
- 10.3. Hospital Pharmacy
- 10.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 10.4. Retail Pharmacy
- 10.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 10.5. Others
- 10.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 11. Competitive Landscape
- 11.1. Recent Developments & Impact Analysis by Key Market Participants
- 11.2. Company Categorization
- 11.3. Participant Overview
- 11.4. Financial Performance
- 11.5. Product Bench Marking
- 11.6. Company Market Share Analysis, 2024
- 11.7. Company Profiles
- 11.7.1. Bayer AG
- 11.7.1.1. Participant's Overview
- 11.7.1.2. Financial Performance
- 11.7.1.3. Product Benchmarking
- 11.7.1.4. Recent Developments/ Strategic Initiatives
- 11.7.2. Boehringer Ingelheim
- 11.7.2.1. Participant's Overview
- 11.7.2.2. Financial Performance
- 11.7.2.3. Product Benchmarking
- 11.7.2.4. Recent Developments/ Strategic Initiatives
- 11.7.3. Merck KGaA
- 11.7.3.1. Participant's Overview
- 11.7.3.2. Financial Performance
- 11.7.3.3. Product Benchmarking
- 11.7.3.4. Recent Developments/ Strategic Initiatives
- 11.7.4. AbbVie Inc.
- 11.7.4.1. Participant's Overview
- 11.7.4.2. Financial Performance
- 11.7.4.3. Product Benchmarking
- 11.7.4.4. Recent Developments/ Strategic Initiatives
- 11.7.5. Evotec SE
- 11.7.5.1. Participant's Overview
- 11.7.5.2. Financial Performance
- 11.7.5.3. Product Benchmarking
- 11.7.5.4. Recent Developments/ Strategic Initiatives
- 11.7.6. Dermapharm Holding SE
- 11.7.6.1. Participant's Overview
- 11.7.6.2. Financial Performance
- 11.7.6.3. Product Benchmarking
- 11.7.6.4. Recent Developments/ Strategic Initiatives
- 11.7.7. BioNTech SE
- 11.7.7.1. Participant's Overview
- 11.7.7.2. Financial Performance
- 11.7.7.3. Product Benchmarking
- 11.7.7.4. Recent Developments/ Strategic Initiatives
- 11.7.8. Sanofi
- 11.7.8.1. Participant's Overview
- 11.7.8.2. Financial Performance
- 11.7.8.3. Product Benchmarking
- 11.7.8.4. Recent Developments/ Strategic Initiatives
- 11.7.9. Biotest AG
- 11.7.9.1. Participant's Overview
- 11.7.9.2. Financial Performance
- 11.7.9.3. Product Benchmarking
- 11.7.9.4. Recent Developments/ Strategic Initiatives
- 11.7.10. F. Hoffmann-La Roche Ltd
- 11.7.10.1. Participant's Overview
- 11.7.10.2. Financial Performance
- 11.7.10.3. Product Benchmarking
- 11.7.10.4. Recent Developments/ Strategic Initiatives
- 11.7.1. Bayer AG
Chapter 12. Conclusion
Product Code: GVR-4-68039-118-0
List of Tables
- Table 1. List of secondary sources
- Table 2. List of abbreviations
- Table 3. Germany Pharmaceutical Market, By Molecule Type, 2021 - 2033 (USD Billion)
- Table 4. Germany Pharmaceutical Market, By Product, 2021 - 2033 (USD Billion)
- Table 5. Germany Pharmaceutical Market, By Type, 2021 - 2033 (USD Billion)
- Table 6. Germany Pharmaceutical Market, By Diseases, 2021 - 2033 (USD Billion)
- Table 7. Germany Pharmaceutical Market, By Route of Administration, 2021 - 2033 (USD Billion)
- Table 8. Germany Pharmaceutical Market, By Age Group, 2021 - 2033 (USD Billion)
- Table 9. Germany Pharmaceutical Market, By Distribution Channel, 2021 - 2033 (USD Billion)
List of Figures
- Fig. 1 Market Research Process
- Fig. 2 Information Procurement
- Fig. 3 Primary Research Pattern
- Fig. 4 Market Research Approaches
- Fig. 5 Value Chain-Based Sizing & Forecasting
- Fig. 6 Market Formulation & Validation
- Fig. 7 Germany Pharmaceutical Market Segmentation
- Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
- Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
- Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
- Fig. 11 Penetration & Growth Prospect Mapping
- Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
- Fig. 13 Porter's Five Forces Analysis
- Fig. 14 Germany pharmaceutical market: Molecule type outlook and key takeaways
- Fig. 15 Germany pharmaceutical market: Molecule type movement analysis & market share 2024 & 2033
- Fig. 16 Biologics & biosimilars (large molecules) market, 2021 - 2033 (USD Billion)
- Fig. 17 Monoclonal Antibodies market, 2021 - 2033 (USD Billion)
- Fig. 18 Vaccines market, 2021 - 2033 (USD Billion)
- Fig. 19 Cell & Gene Therapy market, 2021 - 2033 (USD Billion)
- Fig. 20 Others market, 2021 - 2033 (USD Billion)
- Fig. 21 Conventional drugs (small molecules) market, 2021 - 2033 (USD Billion)
- Fig. 22 Germany pharmaceutical market: Product outlook and key takeaways
- Fig. 23 Germany pharmaceutical market: Product movement analysis & market share 2024 & 2033
- Fig. 24 Branded Germany pharmaceutical market, 2021 - 2033 (USD Billion)
- Fig. 25 Generics Germany pharmaceutical market, 2021 - 2033 (USD Billion)
- Fig. 26 Germany pharmaceutical market: Type outlook and key takeaways
- Fig. 27 Germany pharmaceutical market: Type movement analysis & market share 2024 & 2033
- Fig. 28 Prescription Germany pharmaceutical market, 2021 - 2033 (USD Billion)
- Fig. 29 OTC Germany pharmaceutical market, 2021 - 2033 (USD Billion)
- Fig. 30 Germany pharmaceutical market: Disease outlook and key takeaways
- Fig. 31 Germany pharmaceutical market: Disease movement analysis & market share 2024 & 2033
- Fig. 32 Cancer market, 2021 - 2033 (USD Billion)
- Fig. 33 Cardiovascular diseases market, 2021 - 2033 (USD Billion)
- Fig. 34 Diabetes market, 2021 - 2033 (USD Billion)
- Fig. 35 Infectious Diseases Market, 2021 - 2033 (USD Billion)
- Fig. 36 Neurological disorders market, 2021 - 2033 (USD Billion)
- Fig. 37 Respiratory diseases market, 2021 - 2033 (USD Billion)
- Fig. 38 Autoimmune diseases market, 2021 - 2033 (USD Billion)
- Fig. 39 Mental health disorders market, 2021 - 2033 (USD Billion)
- Fig. 40 Gastrointestinal diseases market, 2021 - 2033 (USD Billion)
- Fig. 41 Women's health diseases market, 2021 - 2033 (USD Billion)
- Fig. 42 Genetic and rare genetic diseases market, 2021 - 2033 (USD Billion)
- Fig. 43 Dermatological conditions market, 2021 - 2033 (USD Billion)
- Fig. 44 Obesity market, 2021 - 2033 (USD Billion)
- Fig. 45 Renal Diseases Market, 2021 - 2033 (USD Billion)
- Fig. 46 Liver conditions market, 2021 - 2033 (USD Billion)
- Fig. 47 Hemotological disorders market, 2021 - 2033 (USD Billion)
- Fig. 48 Eye conditions market, 2021 - 2033 (USD Billion)
- Fig. 49 Infertility conditions market, 2021 - 2033 (USD Billion)
- Fig. 50 Endocrine disorders market, 2021 - 2033 (USD Billion)
- Fig. 51 Allergies market, 2021 - 2033 (USD Billion)
- Fig. 52 Other diseases market, 2021 - 2033 (USD Billion)
- Fig. 53 Germany pharmaceutical market: Route of administration outlook and key takeaways
- Fig. 54 Germany pharmaceutical market: Route of administration movement analysis & market share 2024 & 2033
- Fig. 55 Oral market, 2021 - 2033 (USD Billion)
- Fig. 56 Tablets market, 2021 - 2033 (USD Billion)
- Fig. 57 Capsules market, 2021 - 2033 (USD Billion)
- Fig. 58 Suspensions market, 2021 - 2033 (USD Billion)
- Fig. 59 Other formulation market, 2021 - 2033 (USD Billion)
- Fig. 60 Topical market, 2021 - 2033 (USD Billion)
- Fig. 61 Parenteral market, 2021 - 2033 (USD Billion)
- Fig. 62 Intravenous market, 2021 - 2033 (USD Billion)
- Fig. 63 Intramuscular market, 2021 - 2033 (USD Billion)
- Fig. 64 Inhalations market, 2021 - 2033 (USD Billion)
- Fig. 65 Others market, 2021 - 2033 (USD Billion)
- Fig. 66 Germany pharmaceutical market: Age group outlook and key takeaways
- Fig. 67 Germany pharmaceutical market: Age group movement analysis & market share 2024 & 2033
- Fig. 68 Children & Adolescents market, 2021 - 2033 (USD Billion)
- Fig. 69 Adults market, 2021 - 2033 (USD Billion)
- Fig. 70 Geriatric market, 2021 - 2033 (USD Billion)
- Fig. 71 Germany pharmaceutical market: Distribution Channel outlook and key takeaways
- Fig. 72 Germany pharmaceutical market: Distribution Channel movement analysis & market share 2024 & 2033
- Fig. 73 Hospital Pharmacy market, 2021 - 2033 (USD Billion)
- Fig. 74 Retail Pharmacy market, 2021 - 2033 (USD Billion)
- Fig. 75 Others market, 2021 - 2033 (USD Billion
- Fig. 76 Strategy Mapping
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.